Posts in: investor (2)

Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover
investorpress clippingsvideo
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev SrivastavaJanuary 8, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
IBT: AI meets enzymes
investornutraceuticalsmedicinepress clippings
International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to makeDecember 17, 2025
CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
100× scale-up of NCT production achieved
heltzenpress releaseinvestornutraceuticalsmedicineNCTkorman
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma
investornutraceuticalsmedicinepress clippingscannabinoids
LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and PharmaNovember 20, 2025
Slack Capital report
investorpress clippings
Slack Capital report: EXOZ is a once-in-a-lifetime opportunityNovember 19, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideoNCTcannabinoids
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
Transcript: EXOZ Q3 2025 update
investor
Transcript: EXOZ Q3 2025 updateNovember 14, 2025
EXOZ 2025 Q3 Update
press releaseinvestor
eXoZymes provides third quarter 2025 update at 5PM EST todayNovember 13, 2025
Previous page
Page 2 of 8
Next page